Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression
European Archives of Psychiatry and Clinical Neuroscience · 2025
DOI: 10.1007/s00406-024-01843-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Archives of Psychiatry and Clinical Neuroscience, 2025. Verfasst von Marco Riebel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, University Regensburg, Universitätsstrasse 84, 93053, Regensburg, Germany. Marco.Riebel@medbo.de. Hauptthemen laut MEDLINE: Receptors, GABA, Major Depressive Disorder, Neurosteroids, Pregnanolone. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universität Regensburg.
Themen: Depression
Abstract (Originalsprache)
Recently, the gamma-aminobutyric acid (GABA) system has come into focus for the treatment of anxiety, postpartum depression, and major depressive disorder. Endogenous 3α-reduced steroids such as allopregnanolone are potent positive allosteric modulators of GABA A receptors and have been known for decades. Current industry developments and first approvals by the U.S. food and drug administration (FDA) for the treatment of postpartum depression with exogenous analogues of these steroids represent a major step forward in the field. 3α-reduced steroids target both synaptic and extrasynaptic GABA A receptors, unlike benzodiazepines, which bind to synaptic receptors. The first FDA-approved 3α-reduced steroid for postpartum depression is brexanolone, an intravenous formulation of allopregnanolone. It has been shown to provide rapid relief of depressive symptoms. An orally available 3α-reduced steroid is zuranolone, which also received FDA approval in 2023 for the treatment of postpartum depression. Although a number of studies have been conducted, the efficacy data were not sufficient to achieve approval of zuranolone in major depressive disorder by the FDA in 2023. The most prominent side effects of these 3α-reduced steroids are somnolence, dizziness and headache. In addition to the issue of efficacy, it should be noted that current data limit the use of these compounds to two weeks. An alternative to exogenous 3α-reduced steroids may be the use of substances that induce endogenous neurosteroidogenesis, such as the translocator protein 18 kDa (TSPO) ligand etifoxine. TSPO has been extensively studied for its role in steroidogenesis, in addition to other functions such as anti-inflammatory and neuroregenerative properties. Currently, etifoxine is the only clinically available TSPO ligand in France for the treatment of anxiety disorders. Studies are underway to evaluate its antidepressant potential. Hopefully, neurosteroid research will lead to the development of fast-acting antidepressants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Psychotherapy, University Regensburg, Universitätsstrasse 84, 93053, Regensburg, Germany. Marco.Riebel@medbo.de.
- Department of Psychiatry and Psychotherapy, University Regensburg, Universitätsstrasse 84, 93053, Regensburg, Germany.
- U1195 Inserm and University Paris-Saclay, Le Kremlin-Bicêtre, Paris, 94276, France.
Förderung
- Universität Regensburg
Zitieren
APA
Riebel, M., Brunner, L. M., Nothdurfter, C., Wein, S., Schwarzbach, J., Liere, P., Schumacher, M., & Rupprecht, R. (2025). Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01843-7
Vancouver
Riebel M, Brunner LM, Nothdurfter C, Wein S, Schwarzbach J, Liere P, et al. Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression. European Archives of Psychiatry and Clinical Neuroscience. 2025. doi:10.1007/s00406-024-01843-7
BibTeX
@article{Riebel2025,
author = {Riebel, Marco and Brunner, Lisa-Marie and Nothdurfter, Caroline and Wein, Simon and Schwarzbach, Jens and Liere, Philippe and Schumacher, Michael and Rupprecht, Rainer},
title = {Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression},
journal = {European Archives of Psychiatry and Clinical Neuroscience},
year = {2025},
doi = {10.1007/s00406-024-01843-7}
}
EUVIMED